Asset Details
Do you wish to reserve the book?
CpG DNA as a vaccine adjuvant
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CpG DNA as a vaccine adjuvant
Do you wish to request the book?
CpG DNA as a vaccine adjuvant
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CpG DNA as a vaccine adjuvant
2011
Overview
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines.
Publisher
Taylor & Francis,Expert Reviews Ltd,Informa Healthcare
Subject
/ Adjuvants, Immunologic - administration & dosage
/ Adjuvants, Immunologic - adverse effects
/ Adjuvants, Immunologic - pharmacology
/ Cancer
/ Communicable Disease Control
/ DNA
/ Humans
/ immunity
/ Neoplasms - prevention & control
/ Oligodeoxyribonucleotides - administration & dosage
/ Oligodeoxyribonucleotides - adverse effects
/ Oligodeoxyribonucleotides - pharmacology
/ Tumors
/ vaccine
/ Vaccines
